89 Beaumont Avenue
Health Science Research Facility (HSRF) 218
Burlington, VT 05405
United States
- Postdoctoral Associate, University of Vermont College of Medicine, Burlington, Vermont
- PhD, Biological Sciences, Madurai Kamaraj University, Madurai, India
- MSc, Biotechnology, University of Mysore, Mysore, India
- BSc, Biochemistry, Botany and Zoology, University of Mysore, Mysore, India
Department of Pathology and Laboratory Medicine
Vermont Lung Center
University of Vermont Cancer Center
Cellular, Molecular, and Biomedical Sciences Program
Areas of expertise
- Protein Disulfide Isomerase in asthma/influenza infection/pulmonary fibrosis
- Unfolded Protein Response (ER stress) in lung diseases and cancer
- Redox regulation of inflammatory response and airway remodeling in lung diseases
- Redox-based epithelial dysregulation in pulmonary fibrosis and cancer
BIO
Vikas Anathy, Ph.D. is a Professor and Division Chief of Redox Biology and Pathology in the Department of Pathology & Laboratory Medicine at the University of Vermont Larner College of Medicine, with over 20 years of experience in redox biology and lung pathobiology. He developed expertise in redox signaling and lung disease pathogenesis during postdoctoral training with Drs. Nick Heintz and Yvonne Janssen-Heininger at the University of Vermont.
Dr. Anathy’s research focuses on endoplasmic reticulum (ER) stress responses and oxidative post-translational protein modifications that drive lung disease, including asthma, influenza-induced lung injury, and pulmonary fibrosis. His laboratory has developed novel lung epithelial–specific mouse models targeting apoptotic pathways, ER-resident redox enzymes, mitochondrial fission proteins, and key transcription factors regulating inflammation and remodeling. His group also advances translational strategies, including ER-targeted pharmacologic agents, protein- and antibody-based therapeutics, and enzymatic assays to interrogate ER oxidoreductase function in airway inflammation and acute lung injury.
He has sustained extramural funding from the NIH, American Lung Association, American Thoracic Society, and Parker B. Francis Foundation, and maintains productive academic and industry collaborations. Dr. Anathy serves as a grant reviewer for the NIH, Consulting Editor for JCI Insight, Guest Editor for Frontiers in Physiology, and Co-Chair of the American Lung Association Emerging Pathogen Award panel. His scholarly output includes 67 PubMed-indexed publications, 3,494 citations (H-index 37), and five issued patents with translational potential, underscoring his commitment to advancing ER-redox biology and developing novel inhaled therapies for debilitating lung diseases.
Publications
Dr. Anathy's publications on PubMed
Awards and Achievements
2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)
Bio
Vikas Anathy, Ph.D. is a Professor and Division Chief of Redox Biology and Pathology in the Department of Pathology & Laboratory Medicine at the University of Vermont Larner College of Medicine, with over 20 years of experience in redox biology and lung pathobiology. He developed expertise in redox signaling and lung disease pathogenesis during postdoctoral training with Drs. Nick Heintz and Yvonne Janssen-Heininger at the University of Vermont.
Dr. Anathy’s research focuses on endoplasmic reticulum (ER) stress responses and oxidative post-translational protein modifications that drive lung disease, including asthma, influenza-induced lung injury, and pulmonary fibrosis. His laboratory has developed novel lung epithelial–specific mouse models targeting apoptotic pathways, ER-resident redox enzymes, mitochondrial fission proteins, and key transcription factors regulating inflammation and remodeling. His group also advances translational strategies, including ER-targeted pharmacologic agents, protein- and antibody-based therapeutics, and enzymatic assays to interrogate ER oxidoreductase function in airway inflammation and acute lung injury.
He has sustained extramural funding from the NIH, American Lung Association, American Thoracic Society, and Parker B. Francis Foundation, and maintains productive academic and industry collaborations. Dr. Anathy serves as a grant reviewer for the NIH, Consulting Editor for JCI Insight, Guest Editor for Frontiers in Physiology, and Co-Chair of the American Lung Association Emerging Pathogen Award panel. His scholarly output includes 67 PubMed-indexed publications, 3,494 citations (H-index 37), and five issued patents with translational potential, underscoring his commitment to advancing ER-redox biology and developing novel inhaled therapies for debilitating lung diseases.
Publications
Awards and Achievements
2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)